ReviewInflammatory bowel diseases2016
New Biomarkers for Diagnosing Inflammatory Bowel Disease and Assessing Treatment Outcomes.
Review in Inflammatory bowel diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Short Ileal Microvillus Length Phenotype Associates with Progression from Inflammatory to Complicated Disease Behavior in Pediatric Crohn's Disease.Inflammatory bowel diseases · 2026Article
- Pharmacoepigenetic Biomarkers in Inflammatory Bowel Diseases: A Narrative Review.The Yale journal of biology and medicine · 2025Review
- Leucine-rich alpha-2 glycoprotein for detecting small bowel lesions in Crohn's disease: A critical review and the path forward.World journal of gastrointestinal endoscopy · 2025Article
- The Serum Biomarkers in Ulcerative Colitis.Medeniyet medical journal · 2024Article
- Smart Capsule for Targeted Detection of Inflammation Levels Inside the GI Tract.IEEE transactions on bio-medical engineering · 2024Article
- Review
- Profiling the inflammatory bowel diseases using genetics, serum biomarkers, and smoking information.iScience · 2023Article
- Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn's Disease.Inflammatory bowel diseases · 2022Article
- Potential role of MALT1 as a candidate biomarker of disease surveillance and treatment response prediction in inflammatory bowel disease patients.Journal of clinical laboratory analysis · 2022Article
- Inflammatory Indexes for Assessing the Severity and Disease Progression of Ulcerative Colitis: A Single-Center Retrospective Study.Frontiers in public health · 2022Article
- Enterogenous Microbiotic Markers in the Differential Diagnosis of Crohn's Disease and Intestinal Tuberculosis.Frontiers in immunology · 2022Article
- The reproducibility of skeletal muscle signal intensity on routine magnetic resonance imaging in Crohn's disease.Journal of gastroenterology and hepatology · 2020Article
- Review
- Monitoring of Vedolizumab Infusion Therapy (MOVE-IT) Response With Fecal Inflammation Markers, Ultrasound, and Trough Serum Level in Patients With Ulcerative Colitis: Protocol for a Multicentric, Prospective, Noninterventional Study.JMIR research protocols · 2019Article
- Peripheral blood miR-372 as a biomarker for ulcerative colitis via direct targeting of NLRP12.Experimental and therapeutic medicine · 2019Article
- Cohort profile of the PRoteomic Evaluation and Discovery in an IBD Cohort of Tri-service Subjects (PREDICTS) study: Rationale, organization, design, and baseline characteristics.Contemporary clinical trials communications · 2019Article
- Positive association between leptin serum levels and disease activity on endoscopy in inflammatory bowel disease: A case-control study.Experimental and therapeutic medicine · 2018Article
- Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis.Practical laboratory medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Despite advances in our understanding of the pathophysiology underlying inflammatory bowel disease, there remains a significant need for biomarkers that can differentiate between Crohn's disease and ulcerative colitis with high sensitivity and specificity, in a cost-efficient manner. As the focus on personalized approaches to the delivery of medical treatment increases, new biomarkers are being developed to predict an individual's response to therapy and their overall disease course. In this review, we will outline many of the existing and recently developed biomarkers, detailing their role in the assessment of patients with inflammatory bowel disease. We will identify opportunities for improvement in our biomarkers, including better differentiation between the subtypes of inflammatory bowel disease. We will also discuss new targets and strategies in biomarker development, including combining modalities to create biomarker signatures to improve the ability to predict disease courses and response to therapy among individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.